om-89 [uro-vaxom® ]
Chronic Pelvic Pain Syndrome
AJU Pharm Co., Ltd.Phase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Chronic Pelvic Pain Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE University of Louisville | Phase 4 | BB |
Doxycycline Insel Gruppe AG, University Hospital Bern | Phase 4 | B |
Cernilton University of Giessen | Phase 3 | B |
S-Ketamine Reinier de Graaf Groep | Phase 3 | B |
asp3652 Astellas Pharma Inc | Phase 2 | B |
View all 12 →
Same molecule, other indications
om-89 [uro-vaxom® ] is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →